STING1 and cancer: In this context, an acid-responsive polymeric nanovaccine was constructed to activate the STING pathway and enhance cancer immunotherapy—the nanovaccines were composed of neoantigen and an acid-activatable polymeric conjugate DMXAA (STING agonist) in a nanoplatform.